CHROMADEX CORPORATION (NASDAQ:CDXC) Files An 8-K Results of Operations and Financial Condition

On August 10, 2017, ChromaDex Corporation (the “Company”) issued a press release announcing its earnings for the quarter ended July 1, 2017. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

(d) Exhibits.

ChromaDex Corp. ExhibitEX-99.1 2 ex99-1.htm PRESS RELEASE SEC Connect   Exhibit 99.1 ChromaDex Reports Second Quarter 2017 Financial Results   -Company Reports Revenue of $5.3 Million for Q2 2017- – Continued Progress on Building a Consumer Products Platform Around TruNiagen®-   IRVINE,…To view the full exhibit click here
About CHROMADEX CORPORATION (NASDAQ:CDXC)
Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.